Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,880 total articles

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics, Inc., a clinical-stage biotechnology company, announced the initiation of its clinical trial for CYWC628, an investigational fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs). The company highlighted the importance of this milestone as it transitions from development to clinical execution. It plans to begin pati…

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB Biotherapeutics, Inc. will release its first quarter 2026 financial results on May 12, 2026, followed by a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. The company is a clinical-stage biopharmaceutical firm focused on developing fully human immunoglobulin therapeutics for autoimmune diseases, wi…

BGIN BLOCKCHAIN LIMITED Reveals PortableBTC at Bitcoin 2026

BGIN BLOCKCHAIN LIMITED Reveals PortableBTC at Bitcoin 2026

BGIN BLOCKCHAIN LIMITED revealed its PortableBTC commemorative prototype miner at the Bitcoin 2026 conference, signaling the company's move into Bitcoin mining hardware development and consumer-oriented mining products under its "Crypto for All" vision. The prototype, powered by the company's BT1 ASIC chip, represents a milestone in BGIN's ASIC des…

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

IMUNON, Inc., a clinical-stage biotech developing DNA-mediated immunotherapies, announced its Q1 2026 financial results and business update conference call set for May 12, 2026. The company will provide updates on IMNN-001, its lead DNA-based interleukin-12 immunotherapy in Phase 3 trials for advanced ovarian cancer, and report progress on its clin…

Chanson International Holding Announces 100 for 1 Share Consolidation

Chanson International Holding Announces 100 for 1 Share Consolidation

Chanson International Holding, a China and US-based bakery and beverage products provider listed on Nasdaq under the ticker CHSN, announced a 100-for-1 share consolidation effective May 7, 2026. The consolidation will reduce the total shares outstanding, increase the par value per share, and maintain the current trading symbol under a new CUSIP. Th…

Foremost Clean Energy Advances CLK Uranium Property With Results of MobileMT and Ambient Noise Tomography Surveys Following up Historic High-Grade Showing

Foremost Clean Energy Advances CLK Uranium Property With Results of MobileMT and Ambient Noise Tomography Surveys Following up Historic High-Grade Showing

Foremost Clean Energy Ltd. announced results from its 2025 helicopter-borne MobileMT electromagnetic survey and ambient noise tomography survey at its CLK Uranium Property in Saskatchewan's Athabasca Basin. The surveys identified complex conductive anomalies and structural features associated with high-grade uranium mineralization, supporting refin…

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio announced additional Phase 1a/b data for PALI-2108, a once-daily oral PDE4 inhibitor prodrug selectively activated in the ileum and colon, demonstrating sustained target engagement above IC90, colon-selective pathway modulation, and strong clinical, histologic, and biomarker improvements in ulcerative colitis patients. This supports co…

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa, Inc. has announced a board-led process to evaluate strategic growth alternatives, including partnerships, mergers, or asset transactions, aiming to enhance scale and shareholder value. Concurrently, the company is focusing resources on advancing the Lumee Oxygen platform toward European CE Mark certification and expanding revenue through i…

Forward Industries and RockawayX Co-Lead Strategic Investment in OnRe to Accelerate Onchain Reinsurance on Solana

Forward Industries and RockawayX Co-Lead Strategic Investment in OnRe to Accelerate Onchain Reinsurance on Solana

Forward Industries announced a strategic co-led $5 million Series A investment in OnRe, a Bermuda-licensed onchain reinsurance firm on Solana, alongside RockawayX. Forward intends to deploy up to $25 million into OnRe's token ONyc, which offers yield from reinsurance risk through blockchain integration. This aligns with Forward's strategy to divers…

Eagle Nuclear Energy Announces Commencement of Environmental Baseline Studies in Advance of PFS-Related Drill Program at Aurora

Eagle Nuclear Energy Announces Commencement of Environmental Baseline Studies in Advance of PFS-Related Drill Program at Aurora

Eagle Nuclear Energy Corp. has initiated comprehensive environmental baseline studies prior to a 27,000 ft Pre-Feasibility Study drilling program at its Aurora Uranium Project located on the Oregon-Nevada border. These studies cover hydrology, geochemistry, flora and fauna, wetlands, meteorology, and cultural heritage to facilitate environmental im…

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

Achieve Life Sciences, a specialty pharmaceutical company focused on cytisinicline for nicotine dependence treatment, announced it will release its Q1 2026 financial results and hold a conference call on May 12, 2026. The announcement comes as the FDA is reviewing its New Drug Application with a PDUFA date set for June 20, 2026, potentially approvi…

InterDigital to Present at Four Upcoming Investor Conferences

InterDigital to Present at Four Upcoming Investor Conferences

InterDigital, Inc., a leading wireless, video, and AI technology research and development company, announced it will present at four major investor conferences between May and June 2026. These presentations will showcase the company's latest technological advancements and strategic outlook in wireless communications, video processing, and AI sector…

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics, Inc. has launched a second clinical trial site in Australia for its Phase IIa study of ONP-002, a novel intranasal neurosteroid designed to treat concussion and mild traumatic brain injury (mTBI). The ongoing trial aims to enroll 40 patients and has already dosed four patients at the first site, reflecting strong demand due to the lack o…

Virtuix to Lead Infantry Training Project for U.S. Marine Corps

Virtuix to Lead Infantry Training Project for U.S. Marine Corps

Virtuix Inc. (NASDAQ: VTIX) has been chosen by the U.S. Marine Corps Training and Education Command to lead the development and integration of a multi-user virtual reality infantry training system utilizing four Omni One omni-directional treadmills. This system allows a four-person Marine fire team to physically move together in a shared virtual en…